TWI896700B - 一種抗IgE的工程化抗體及其應用 - Google Patents

一種抗IgE的工程化抗體及其應用

Info

Publication number
TWI896700B
TWI896700B TW110125327A TW110125327A TWI896700B TW I896700 B TWI896700 B TW I896700B TW 110125327 A TW110125327 A TW 110125327A TW 110125327 A TW110125327 A TW 110125327A TW I896700 B TWI896700 B TW I896700B
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
antigen
binding protein
Prior art date
Application number
TW110125327A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214703A (zh
Inventor
鄧俗俊
顧春銀
劉小五
曹曉丹
劉培培
張建建
潘忠宗
肖政
王學萍
郭海兵
Original Assignee
大陸商上海濟煜醫藥科技有限公司
大陸商江西濟民可信集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海濟煜醫藥科技有限公司, 大陸商江西濟民可信集團有限公司 filed Critical 大陸商上海濟煜醫藥科技有限公司
Publication of TW202214703A publication Critical patent/TW202214703A/zh
Application granted granted Critical
Publication of TWI896700B publication Critical patent/TWI896700B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110125327A 2020-07-10 2021-07-09 一種抗IgE的工程化抗體及其應用 TWI896700B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010663029 2020-07-10
CN202010663029.3 2020-07-10
CN202110750959.7 2021-07-01
CN202110750959 2021-07-01

Publications (2)

Publication Number Publication Date
TW202214703A TW202214703A (zh) 2022-04-16
TWI896700B true TWI896700B (zh) 2025-09-11

Family

ID=79552269

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110125327A TWI896700B (zh) 2020-07-10 2021-07-09 一種抗IgE的工程化抗體及其應用

Country Status (11)

Country Link
US (1) US20230250191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4180454A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023541217A (cg-RX-API-DMAC7.html)
KR (1) KR20230042030A (cg-RX-API-DMAC7.html)
CN (1) CN116018352A (cg-RX-API-DMAC7.html)
AU (1) AU2021306786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185192A1 (cg-RX-API-DMAC7.html)
IL (1) IL299747A (cg-RX-API-DMAC7.html)
TW (1) TWI896700B (cg-RX-API-DMAC7.html)
WO (1) WO2022007965A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268176A (zh) * 1997-07-02 2000-09-27 基因技术股份有限公司 改进的抗lgE抗体以及改进多肽的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4342541A3 (en) * 2017-04-07 2024-07-03 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3788078A4 (en) * 2018-05-04 2022-03-02 Allakos Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268176A (zh) * 1997-07-02 2000-09-27 基因技术股份有限公司 改进的抗lgE抗体以及改进多肽的方法

Also Published As

Publication number Publication date
US20230250191A1 (en) 2023-08-10
EP4180454A4 (en) 2024-10-02
KR20230042030A (ko) 2023-03-27
IL299747A (en) 2023-03-01
JP2026071342A (ja) 2026-04-28
CN116018352A (zh) 2023-04-25
WO2022007965A1 (zh) 2022-01-13
CA3185192A1 (en) 2022-01-13
EP4180454A9 (en) 2023-07-26
EP4180454A1 (en) 2023-05-17
AU2021306786A1 (en) 2023-02-16
BR112023000400A2 (pt) 2023-03-21
JP2023541217A (ja) 2023-09-29
TW202214703A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
TWI851860B (zh) 抗tslp抗體及其用途
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
DK2097455T3 (en) HUMANIZED ANTI-FACTOR D ANTIBODIES
CN101939337B (zh) 抗trka抗体及其衍生物
TWI860014B (zh) 抗體
BRPI0712953A2 (pt) anticorpos anti-nkg2a e suas utilizações
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
PT2115003E (pt) Anticorpos humanos que se ligam ao ligando 4 semelhante ao ligando delta humano
KR20220131970A (ko) 항-st2 항체 및 그의 적용
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2026071342A (ja) 抗IgE改変抗体及びその適用
AU2024219840A1 (en) Anti-tnfalpha-antibodies and functional fragments thereof
TW202332692A (zh) 抗體
IL297638A (en) Compounds and methods targeting interleukin-34
WO2022063281A1 (zh) 结合人il-33的抗体、其制备方法和用途
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
TW202317643A (zh) 用於抗pacap抗體的組合物和方法
CN113366020B (zh) 抗pd-l1的新型抗体及其用途
TW202540170A (zh) 抗原結合蛋白
WO2024255683A1 (zh) 抗bdca2抗体
CN118488967A (zh) 半乳凝素-10抗体
TWI891929B (zh) 分離的抗原結合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
JP2025524927A (ja) カンナビノイド受容体1型結合タンパク質及びその使用
WO2025185773A1 (zh) 靶向tl1a的抗体及其应用